{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:01Z","timestamp":1794047461510,"version":"4.8.0"},"reference-count":51,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>T-cell-engaging bispecific antibody (T-BsAb, also known as BiTE) therapy has emerged as a powerful therapeutic modality against multiple myeloma. Given that T-BsAb therapy redirects endogenous T cells to eliminate tumor cells, reinvigorating dysfunctional T cells may be a potential approach to improve the efficacy of T-BsAb. While various immunostimulatory cytokines can potentiate effector T-cell functions, the optimal cytokine treatment for T-BsAb therapy is yet to be established, partly due to a concern of cytokine release syndrome driven by aberrant interferon (IFN)-\u03b3 production. Here, we functionally screen immunostimulatory cytokines to determine an ideal combination partner for T-BsAb therapy. This approach reveals interleukin (IL)-21 as a potential immunostimulatory cytokine with the ability to augment T-BsAb-mediated release of granzyme B and perforin, without increasing IFN-\u03b3 release. Transcriptome profiling and functional characterization strongly support that IL-21 selectively targets the cytotoxic granule exocytosis pathway, but not pro-inflammatory responses. Notably, IL-21 modulates multiple steps of cytotoxic effector functions including upregulation of co-activating CD226 receptor, increasing cytotoxic granules, and promoting cytotoxic granule delivery at the immunological synapse. Indeed, T-BsAb-mediated myeloma killing is cytotoxic granule-dependent, and IL-21 priming significantly augments cytotoxic activities. Furthermore, in vivo IL-21 treatment induces cytotoxic effector reprogramming in bone marrow T cells, showing synergistic anti-myeloma effects in combination with T-BsAb therapy. Together, harnessing the cytotoxic granule exocytosis pathway by IL-21 may be a potential approach to achieve better responses by T-BsAb therapy.<\/jats:p>","DOI":"10.3324\/haematol.2023.284435","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:10:02Z","timestamp":1706152202000},"page":"2131-2143","source":"Crossref","is-referenced-by-count":3,"title":["Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy"],"prefix":"10.3324","volume":"109","author":[{"given":"Mika","family":"Casey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Hoyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Yu","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soi Cheng","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"63163","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk N. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"63164","doi-asserted-by":"crossref","unstructured":"Chari A, Minnema MC, Berdeja JG. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387(24):2232-2244.","DOI":"10.1056\/NEJMoa2204591"},{"key":"63165","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"63166","doi-asserted-by":"crossref","unstructured":"Casey M, Nakamura K. The cancer-immunity cycle in multiple myeloma. Immunotargets Ther. 2021; 10:247-260.","DOI":"10.2147\/ITT.S305432"},{"key":"63167","doi-asserted-by":"crossref","unstructured":"Cohen AD, Harrison SJ, Krishnan A. Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in relapsed\/refractory multiple myeloma. Blood. 2020; 136(Suppl 1):42-43.","DOI":"10.1182\/blood-2020-136985"},{"key":"63168","doi-asserted-by":"crossref","unstructured":"Lee H, Ahn S, Maity R. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023; 29(9):2295-2306.","DOI":"10.1038\/s41591-023-02491-5"},{"key":"63169","doi-asserted-by":"crossref","unstructured":"Friedrich MJ, Neri P, Kehl N. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023; 41(4):711-725.","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"63170","doi-asserted-by":"crossref","unstructured":"Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020; 136(24):2731-2740.","DOI":"10.1182\/blood.2020006540"},{"key":"63171","doi-asserted-by":"crossref","unstructured":"Tirier SM, Mallm J-P, Steiger S. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nature Commun. 2021; 12(1):6960.","DOI":"10.1038\/s41467-021-26951-z"},{"key":"63172","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV. The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception. Am J Hematol. 2023; 98(Suppl 2):S4-S12.","DOI":"10.1002\/ajh.26752"},{"key":"63173","doi-asserted-by":"crossref","unstructured":"Casey M, Tu C, Harrison SJ, Nakamura K. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. Blood Adv. 2022; 6(17):5165-5170.","DOI":"10.1182\/bloodadvances.2022008118"},{"key":"63174","doi-asserted-by":"crossref","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019; 120(1):6-15.","DOI":"10.1038\/s41416-018-0328-y"},{"key":"63175","doi-asserted-by":"crossref","unstructured":"Nakamura K, Bald T, Smyth MJ. Cancer-killing, decoy-resistant interleukin-18. Immunol Cell Biol. 2020; 98(6):434-436.","DOI":"10.1111\/imcb.12359"},{"key":"63176","doi-asserted-by":"crossref","unstructured":"Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018; 10(12):a028472.","DOI":"10.1101\/cshperspect.a028472"},{"key":"63177","doi-asserted-by":"crossref","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22(2):85-96.","DOI":"10.1038\/s41577-021-00547-6"},{"key":"63178","doi-asserted-by":"crossref","unstructured":"Li J, Piskol R, Ybarra R. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019; 11(508):eaax8861.","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"63179","doi-asserted-by":"crossref","unstructured":"Sterner RM, Sakemura R, Cox MJ. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019; 133(7):697-709.","DOI":"10.1182\/blood-2018-10-881722"},{"key":"63180","doi-asserted-by":"crossref","unstructured":"Bailey SR, Vatsa S, Larson RC. Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 2022; 3(2):136-153.","DOI":"10.1158\/2643-3230.BCD-21-0181"},{"key":"63181","doi-asserted-by":"crossref","unstructured":"Manni S, Del Bufalo F, Merli P. Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023; 14(1):3423.","DOI":"10.1038\/s41467-023-38723-y"},{"key":"63182","doi-asserted-by":"crossref","unstructured":"Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015; 15(6):388-400.","DOI":"10.1038\/nri3839"},{"key":"63183","doi-asserted-by":"crossref","unstructured":"La Ros\u00e9e P, Horne A, Hines M. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019; 133(23):2465-2477.","DOI":"10.1182\/blood.2018894618"},{"key":"63184","doi-asserted-by":"crossref","unstructured":"Ishii K, Pouzolles M, Chien CD. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 2020; 130(10):5425-5443.","DOI":"10.1172\/JCI130059"},{"key":"63185","doi-asserted-by":"crossref","unstructured":"Larson RC, Kann MC, Bailey SR. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature. 2022; 604(7906):563-570.","DOI":"10.1038\/s41586-022-04585-5"},{"key":"63186","doi-asserted-by":"crossref","unstructured":"Casey M, Lee C, Kwok W. Regulatory T cells hamper the efficacy of T cell-engaging bispecific antibody therapy. Haematologica. 2024; 109(3):787-789.","DOI":"10.3324\/haematol.2023.283758"},{"key":"63187","doi-asserted-by":"crossref","unstructured":"Casey M, Segawa K, Law SC. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia. 2023; 37(2):379-387.","DOI":"10.1038\/s41375-022-01794-9"},{"key":"63188","doi-asserted-by":"crossref","unstructured":"Nakamura K, Kassem S, Cleynen A. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018; 33(4):634-648.","DOI":"10.1016\/j.ccell.2018.02.007"},{"key":"63189","doi-asserted-by":"crossref","unstructured":"Lewis KE, Selby MJ, Masters G. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. Oncoimmunology. 2017; 7(1):e1377873.","DOI":"10.1080\/2162402X.2017.1377873"},{"key":"63190","doi-asserted-by":"crossref","unstructured":"Mittal D, Caramia F, Michiels S. Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+ T cells. Cancer Res. 2016; 76(2):264-274.","DOI":"10.1158\/0008-5472.CAN-15-1567"},{"key":"63191","doi-asserted-by":"crossref","unstructured":"Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010; 22(3):333-340.","DOI":"10.1016\/j.coi.2010.02.013"},{"key":"63192","doi-asserted-by":"crossref","unstructured":"Weulersse M, Asrir A, Pichler AC. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell antitumor functions and limits the efficacy of cancer immunotherapy. Immunity. 2020; 53(4):824-839.","DOI":"10.1016\/j.immuni.2020.09.006"},{"key":"63193","doi-asserted-by":"crossref","unstructured":"Braun M, Aguilera AR, Sundarrajan A. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity. 2020; 53(4):805-823.","DOI":"10.1016\/j.immuni.2020.09.010"},{"key":"63194","doi-asserted-by":"crossref","unstructured":"Chung DJ, Pronschinske KB, Shyer JA. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016; 4(1):61-71.","DOI":"10.1158\/2326-6066.CIR-15-0055"},{"key":"63195","doi-asserted-by":"crossref","unstructured":"Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol. 2009; 9(9):630-644.","DOI":"10.1038\/nri2606"},{"key":"63196","doi-asserted-by":"crossref","unstructured":"Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci. 2016; 129(15):2881-2886.","DOI":"10.1242\/jcs.186205"},{"key":"63197","doi-asserted-by":"crossref","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):116.","DOI":"10.1186\/s13045-016-0345-3"},{"key":"63198","doi-asserted-by":"crossref","unstructured":"Bailur JK, McCachren SS, Doxie DB. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019; 5(11)","DOI":"10.1172\/jci.insight.127807"},{"key":"63199","doi-asserted-by":"crossref","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018; 36(4):346-351.","DOI":"10.1038\/nbt.4086"},{"key":"63200","doi-asserted-by":"crossref","unstructured":"Wilkens AB, Fulton EC, Pont MJ. NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness. Blood. 2022; 140(21):2261-2275.","DOI":"10.1182\/blood.2021015144"},{"key":"63201","doi-asserted-by":"crossref","unstructured":"Rainone M, Ngo D, Baird JH. Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/ hemophagocytic lymphohistiocytosis. Blood Adv. 2023; 7(4):533-536.","DOI":"10.1182\/bloodadvances.2022008256"},{"key":"63202","doi-asserted-by":"crossref","unstructured":"Monteleone G, Monteleone I, Fina D. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn\u2019s disease. Gastroenterology. 2005; 128(3):687-694.","DOI":"10.1053\/j.gastro.2004.12.042"},{"key":"63203","doi-asserted-by":"crossref","unstructured":"Suto A, Wurster AL, Reiner SL, Grusby MJ. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol. 2006; 177(6):3721-3727.","DOI":"10.4049\/jimmunol.177.6.3721"},{"key":"63204","doi-asserted-by":"crossref","unstructured":"Tian Y, Zajac AJ. IL-21 and T cell differentiation: consider the context. Trends Immunol. 2016; 37(8):557-568.","DOI":"10.1016\/j.it.2016.06.001"},{"key":"63205","doi-asserted-by":"crossref","unstructured":"Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014; 13(5):379-395.","DOI":"10.1038\/nrd4296"},{"key":"63206","doi-asserted-by":"crossref","unstructured":"White L, Krishnan S, Strbo N. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood. 2007; 109(9):3873-3880.","DOI":"10.1182\/blood-2006-09-045278"},{"key":"63207","doi-asserted-by":"crossref","unstructured":"Browning RL, Byrd WH, Gupta N. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res. 2016; 4(8):698-707.","DOI":"10.1158\/2326-6066.CIR-15-0291"},{"key":"63208","doi-asserted-by":"crossref","unstructured":"Meermeier EW, Welsh SJ, Sharik ME. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021; 2(4):354-369.","DOI":"10.1158\/2643-3230.BCD-21-0038"},{"key":"63209","doi-asserted-by":"crossref","unstructured":"Li Y, Cong Y, Jia M. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nat Commun. 2021; 12(1):951.","DOI":"10.1038\/s41467-021-21241-0"},{"key":"63210","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Byrd JC, Andorsky DJ. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012; 18(20):5752-5760.","DOI":"10.1158\/1078-0432.CCR-12-0456"},{"key":"63211","doi-asserted-by":"crossref","unstructured":"Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002; 99(10):3756-3762.","DOI":"10.1182\/blood.V99.10.3756"},{"key":"63212","doi-asserted-by":"crossref","unstructured":"Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010; 115(3):570-580.","DOI":"10.1182\/blood-2009-08-239996"},{"key":"63213","doi-asserted-by":"crossref","unstructured":"Gowda A, Roda J, Hussain SR. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008; 111(9):4723-4730.","DOI":"10.1182\/blood-2007-07-099531"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284435\/76507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284435\/77174","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11421\/76507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:34Z","timestamp":1794045934000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284435","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}